Literature DB >> 33288886

NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration.

Bayram Edemir1, Carsten Müller-Tidow2,3, Chunhong Cui4,5, Yi Liu4, Dennis Gerloff1,6, Christian Rohde4, Cornelius Pauli1, Marcel Köhn7, Danny Misiak7, Thomas Oellerich8,9,10, Schraga Schwartz11, Lars-Henning Schmidt12,13, Rainer Wiewrodt12, Alessandro Marra14, Ludger Hillejan15, Frank Bartel16, Claudia Wickenhauser16, Stefan Hüttelmaier7, Stefanie Göllner4, Fengbiao Zhou4.   

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide underlining the urgent need for new biomarkers and therapeutic targets for this disease. Long noncoding RNAs are critical players in NSCLC but the role of small RNA species is not well understood. In the present study, we investigated the role of H/ACA box small nucleolar RNAs (snoRNAs) and snoRNA-bound ribonucleoproteins (snoRNPs) in the tumorigenesis of NSCLC. H/ACA box snoRNPs including the NOP10 core protein were highly expressed in NSCLC. High levels of either NOP10 mRNA or protein were associated with poor prognosis in NSCLC patients. Loss of NOP10 and subsequent reduction of H/ACA box snoRNAs and rRNA pseudouridylation inhibited lung cancer cell growth, colony formation, migration, and invasion. A focused CRISPR/Cas9 snoRNA knockout screen revealed that genomic deletion of SNORA65, SNORA7A, and SNORA7B reduced proliferation of lung cancer cells. In line, high levels of SNORA65, SNORA7A, and SNORA7B were observed in primary lung cancer specimens with associated changes in rRNA pseudouridylation. Knockdown of either SNORA65 or SNORA7A/B inhibited growth and colony formation of NSCLC cell lines. Our data indicate that specific H/ACA box snoRNAs and snoRNA-associated proteins such as NOP10 have an oncogenic role in NSCLC providing new potential biomarkers and therapeutic targets for the disease.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33288886      PMCID: PMC7862062          DOI: 10.1038/s41388-020-01570-y

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

Review 1.  Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs.

Authors:  T Kiss
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

Review 2.  Small RNAs with big implications: new insights into H/ACA snoRNA function and their role in human disease.

Authors:  Mary McMahon; Adrian Contreras; Davide Ruggero
Journal:  Wiley Interdiscip Rev RNA       Date:  2014-10-31       Impact factor: 9.957

Review 3.  Non-coding RNAs: regulators of disease.

Authors:  Ryan J Taft; Ken C Pang; Timothy R Mercer; Marcel Dinger; John S Mattick
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

4.  A Cajal body-specific pseudouridylation guide RNA is composed of two box H/ACA snoRNA-like domains.

Authors:  Arnold M Kiss; Beáta E Jády; Xavier Darzacq; Céline Verheggen; Edouard Bertrand; Tamás Kiss
Journal:  Nucleic Acids Res       Date:  2002-11-01       Impact factor: 16.971

5.  The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth.

Authors:  Lars Henning Schmidt; Tilmann Spieker; Steffen Koschmieder; Sonja Schäffers; Julia Humberg; Dominik Jungen; Etmar Bulk; Antje Hascher; Danielle Wittmer; Alessandro Marra; Ludger Hillejan; Karsten Wiebe; Wolfgang E Berdel; Rainer Wiewrodt; Carsten Muller-Tidow
Journal:  J Thorac Oncol       Date:  2011-12       Impact factor: 15.609

6.  MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.

Authors:  Ping Ji; Sven Diederichs; Wenbing Wang; Sebastian Böing; Ralf Metzger; Paul M Schneider; Nicola Tidow; Burkhard Brandt; Horst Buerger; Etmar Bulk; Michael Thomas; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Oncogene       Date:  2003-09-11       Impact factor: 9.867

Review 7.  Heterogeneity in Lung Cancer.

Authors:  Vitor Manuel Leitão de Sousa; Lina Carvalho
Journal:  Pathobiology       Date:  2018-04-10       Impact factor: 4.342

Review 8.  Lung Cancer Statistics.

Authors:  Lindsey A Torre; Rebecca L Siegel; Ahmedin Jemal
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

9.  U3, U8 and U13 comprise a new class of mammalian snRNPs localized in the cell nucleolus.

Authors:  K Tyc; J A Steitz
Journal:  EMBO J       Date:  1989-10       Impact factor: 11.598

Review 10.  Noncoding RNAs in disease.

Authors:  Evangelia Lekka; Jonathan Hall
Journal:  FEBS Lett       Date:  2018-07-20       Impact factor: 4.124

View more
  13 in total

1.  Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.

Authors:  Yue Zhuo; Shujun Li; Wei Hu; Yu Zhang; Yufan Shi; Faxue Zhang; Jian Zhang; Juan Wang; Meijuan Liao; Jiahao Chen; Huiling Qian; Dejia Li; Chengcao Sun
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

Review 2.  CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.

Authors:  Fatima Akram; Ikram Ul Haq; Sania Sahreen; Narmeen Nasir; Waqas Naseem; Memoona Imitaz; Amna Aqeel
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

3.  H/ACA snoRNP Gene Family as Diagnostic and Prognostic Biomarkers for Hepatocellular Carcinoma.

Authors:  Mi Zhang; Wei Zhao; Shanshan Liu; Haichuan Liu; Liang Liu; Qiling Peng; Chengyou Du; Ning Jiang
Journal:  Pharmgenomics Pers Med       Date:  2021-10-19

4.  Analysis of Telomere Maintenance Related Genes Reveals NOP10 as a New Metastatic-Risk Marker in Pheochromocytoma/Paraganglioma.

Authors:  María Monteagudo; Paula Martínez; Luis J Leandro-García; Ángel M Martínez-Montes; Bruna Calsina; Marta Pulgarín-Alfaro; Alberto Díaz-Talavera; Sara Mellid; Rocío Letón; Eduardo Gil; Manuel Pérez-Martínez; Diego Megías; Raúl Torres-Ruiz; Sandra Rodriguez-Perales; Patricia González; Eduardo Caleiras; Scherezade Jiménez-Villa; Giovanna Roncador; Cristina Álvarez-Escolá; Rita M Regojo; María Calatayud; Sonsoles Guadalix; Maria Currás-Freixes; Elena Rapizzi; Letizia Canu; Svenja Nölting; Hanna Remde; Martin Fassnacht; Nicole Bechmann; Graeme Eisenhofer; Massimo Mannelli; Felix Beuschlein; Marcus Quinkler; Cristina Rodríguez-Antona; Alberto Cascón; María A Blasco; Cristina Montero-Conde; Mercedes Robledo
Journal:  Cancers (Basel)       Date:  2021-09-23       Impact factor: 6.575

Review 5.  Gene editing and its applications in biomedicine.

Authors:  Guanglei Li; Xiangyang Li; Songkuan Zhuang; Liren Wang; Yifan Zhu; Yangcan Chen; Wen Sun; Zeguang Wu; Zhuo Zhou; Jia Chen; Xingxu Huang; Jin Wang; Dali Li; Wei Li; Haoyi Wang; Wensheng Wei
Journal:  Sci China Life Sci       Date:  2022-02-18       Impact factor: 10.372

6.  Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma.

Authors:  Yupeng Jiang; Wenhao Ouyang; Chenzi Zhang; Yunfang Yu; Herui Yao
Journal:  Front Cell Dev Biol       Date:  2022-01-20

Review 7.  snoRNAs: functions and mechanisms in biological processes, and roles in tumor pathophysiology.

Authors:  Zheng-Hao Huang; Yu-Ping Du; Jing-Tao Wen; Bing-Feng Lu; Yang Zhao
Journal:  Cell Death Discov       Date:  2022-05-12

8.  CDK1 promotes the stemness of lung cancer cells through interacting with Sox2.

Authors:  Z Huang; G Shen; J Gao
Journal:  Clin Transl Oncol       Date:  2021-03-15       Impact factor: 3.405

9.  Comparative Transcriptional Analysis of Pulmonary Arterial Hypertension Associated With Three Different Diseases.

Authors:  Wei Wang; Zhenhong Jiang; Dandan Zhang; Linghua Fu; Rong Wan; Kui Hong
Journal:  Front Cell Dev Biol       Date:  2021-07-15

10.  High-grade ovarian cancer associated H/ACA snoRNAs promote cancer cell proliferation and survival.

Authors:  Laurence Faucher-Giguère; Audrey Roy; Gabrielle Deschamps-Francoeur; Sonia Couture; Ryan M Nottingham; Alan M Lambowitz; Michelle S Scott; Sherif Abou Elela
Journal:  NAR Cancer       Date:  2022-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.